These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 33207975)

  • 21. Accuracy of first-trimester combined test in screening for trisomies 21, 18 and 13.
    Santorum M; Wright D; Syngelaki A; Karagioti N; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Jun; 49(6):714-720. PubMed ID: 27549925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
    Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
    Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.
    Karadzov-Orlić N; Egić A; Filimonović D; Marinković M; Damnjanović-Pazin B; Milovanović Z; Joksić I; Branković S; Lukić R; Mandić V; Cerović N; Mojović D; Plamenac S; Stanković M; Maglić D; Mikovć Z
    Srp Arh Celok Lek; 2012; 140(9-10):606-11. PubMed ID: 23289277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-trimester screening for trisomy 21 in twin pregnancy: does the addition of biochemistry make an improvement?
    Goncé A; Borrell A; Fortuny A; Casals E; Martínez MA; Mercadé I; Cararach V; Vanrell JA
    Prenat Diagn; 2005 Dec; 25(12):1156-61. PubMed ID: 16231401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First- and second-trimester screening: detection of aneuploidies other than Down syndrome.
    Breathnach FM; Malone FD; Lambert-Messerlian G; Cuckle HS; Porter TF; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Klugman S; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Tripp T; Bianchi DW; D'Alton ME;
    Obstet Gynecol; 2007 Sep; 110(3):651-7. PubMed ID: 17766613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of first-trimester combined test results in preparation for a cell-free fetal DNA era.
    Kose S; Cımrın D; Yıldırım N; Aksel O; Keskinoglu P; Bora E; Cankaya T; Altunyurt S
    Int J Gynaecol Obstet; 2016 Nov; 135(2):187-191. PubMed ID: 27569022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Hoopmann M; Abele H; Alkier R; Lüthgens K
    Ultrasound Obstet Gynecol; 2012 Nov; 40(5):530-5. PubMed ID: 22611005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency.
    Orlandi F; Damiani G; Hallahan TW; Krantz DA; Macri JN
    Ultrasound Obstet Gynecol; 1997 Dec; 10(6):381-6. PubMed ID: 9476320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
    Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
    J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation.
    Kagan KO; Valencia C; Livanos P; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2009 Jan; 33(1):18-22. PubMed ID: 19031473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum parameters and nuchal translucency in first trimester screening for fetal chromosomal abnormalities.
    Zimmermann R; Hucha A; Savoldelli G; Binkert F; Achermann J; Grudzinskas JG
    Br J Obstet Gynaecol; 1996 Oct; 103(10):1009-14. PubMed ID: 8863700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A 1st-trimester combined screening test in pregnant women of advanced maternal age in a Chinese population.
    Pan M; Han J; Yang X; Zhen L; Liao C; Li DZ
    J Obstet Gynaecol; 2015 Feb; 35(2):121-4. PubMed ID: 25057869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany.
    Soergel P; Pruggmayer M; Schwerdtfeger R; Muhlhaus K; Scharf A
    Fetal Diagn Ther; 2006; 21(3):264-8. PubMed ID: 16601335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening for trisomy at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
    Mazer Zumaeta A; Wright A; Syngelaki A; Maritsa VA; Bardani E; Nicolaides KH
    Ultrasound Obstet Gynecol; 2020 Sep; 56(3):408-415. PubMed ID: 32621353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Routine first-trimester screening for fetal trisomies in twin pregnancy: cell-free DNA test contingent on results from combined test.
    Galeva S; Konstantinidou L; Gil MM; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2019 Feb; 53(2):208-213. PubMed ID: 30353581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First trimester combined screening in patients with systemic lupus erythematosus: impact of pre-analytical variables on risk assessment.
    de Sousa MJR; Ribeiro R; Syngelaki A; Nicolaides KH
    Clin Rheumatol; 2019 May; 38(5):1251-1255. PubMed ID: 30919147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical use of first-trimester aneuploidy screening in a United States population can replicate data from clinical trials.
    Perni SC; Predanic M; Kalish RB; Chervenak FA; Chasen ST
    Am J Obstet Gynecol; 2006 Jan; 194(1):127-30. PubMed ID: 16389021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved diagnostic accuracy by using secondary ultrasound markers in the first-trimester screening for trisomies 21, 18 and 13 and Turner syndrome.
    Karadzov-Orlic N; Egic A; Milovanovic Z; Marinkovic M; Damnjanovic-Pazin B; Lukic R; Joksic I; Curkovic A; Mikovic Z
    Prenat Diagn; 2012 Jul; 32(7):638-43. PubMed ID: 22570267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical usefulness of biochemical (free β-hCg, PaPP-a) and ultrasound (nuchal translucency) parameters in prenatal screening of trisomy 21 in the first trimester of pregnancy.
    Ziolkowska K; Dydowicz P; Sobkowski M; Tobola-Wrobel K; Wysocka E; Pietryga M
    Ginekol Pol; 2019; 90(3):161-166. PubMed ID: 30950006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.